A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/00 (2006.01) A61K 47/40 (2006.01) A61K 51/10 (2006.01)
Patent
CA 2513331
The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula NH2-Gly Tyr Tyr Tip Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooH; and a substituted 13-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition ha.s a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.
L'invention concerne une composition pharmaceutique contenant un excipient aqueux, de 0,1 mg/ml à 20 mg/ml de la composition d'un sel acceptable d'un point de vue pharmaceutique d'un peptide représenté par la formule structurelle NH¿2?-Gly Tyr Tyr Tip Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-cooH, et une quantité suffisante d'une 13-cyclodextrine substituée pour dissoudre le peptide dans l'excipient aqueux, la composition ayant un pH situé entre 4 et 9. L'invention concerne également un procédé de préparation de ladite composition, ainsi qu'une méthode de soulagement des symptômes du lupus érythémateux systémique (SLE) chez un sujet humain, consistant à administrer ladite composition pharmaceutique au sujet.
Cohen-Vered Sharon
Gilbert Adrian
Klinger Ety
Naftali Esmira
Weinstein Vera
Heenan Blaikie Llp
Teva Pharmaceutical Industries Ltd
LandOfFree
Parenteral formulations of a peptide for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Parenteral formulations of a peptide for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Parenteral formulations of a peptide for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1561816